Why Teladoc (TDOC) Shares Are Getting Obliterated Today

What Happened?

Shares of digital medical services platform Teladoc Health (NYSE:TDOC) fell 6% in the afternoon session after analyst forecasts pointed to a significant slowdown in the company's future growth compared to the broader industry. Analysts watching the company estimated its growth at only 2.2% per year over the next three years. In contrast, the rest of the healthcare technology industry was projected to expand by a much more attractive 12% annually. This large gap in expected performance likely made investors uncomfortable, as it suggested Teladoc could be facing a less prosperous future than its peers.

The shares closed the day at $8.13, down 5.8% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Teladoc? Access our full analysis report here.

What Is The Market Telling Us

Teladoc’s shares are extremely volatile and have had 48 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 4 days ago when the stock gained 6.3% on the news that the company reported third-quarter financial results that surpassed Wall Street's revenue expectations, even as other key metrics declined compared to the previous year. Teladoc posted revenue of $626.4 million, which represented a 2.2% year-over-year decline but came in slightly ahead of analyst forecasts. The company's adjusted EBITDA of $66.07 million also topped estimates. However, the company's GAAP loss of $0.28 per share was wider than Wall Street had anticipated. The stock's positive reaction suggests investors focused on the revenue and EBITDA beats, viewing the results as better than feared. Adding to this sentiment, Teladoc's revenue guidance for the next quarter was roughly in line with expectations, reassuring investors about the near-term outlook.

Teladoc is down 15.1% since the beginning of the year, and at $8.08 per share, it is trading 43.6% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc’s shares 5 years ago would now be looking at an investment worth $41.38.

P.S. In tech investing, "Gorillas" are the rare companies that dominate their markets—like Microsoft and Apple did decades ago. Today, the next Gorilla is emerging in AI-powered enterprise software. Access the ticker here in our special report.